Study: Vaccinated pregnant women pass COVID antibodies to babies

New COVID-19 research indicates pregnant women who received the Pfizer/BioNTech or Moderna vaccines pass high levels of protective antibodies to their babies.

These findings were reported in the American Journal of Obstetrics and Gynecology-Maternal Fetal Medicine and approved by the Institutional Review Board — an institution designated to review and monitor biomedical research involving human subjects.

The study involved 36 newborn babies whose mothers had received at least one dose of Pfizer/BioNTech or Moderna. It indicated babies had antibodies that targeted the spike protein found on the surface of the coronavirus.

The doctors analysed blood samples from these babies’ umbilical cord and the antibodies found could be traced to the mothers’ vaccination.

In an interview with international news organisation, Reuters, co-author of the research and a research scientist at NYU Langone Health in New York City Dr, Ashely Roman said “the antibodies that the mother is building to the vaccine are crossing the placenta and that’s likely to confer benefits for the infant after it is born”.

Dr Roman said it is not yet clear if the timing of the vaccination during pregnancy impacts the level of antibodies found in the baby. She further said the research does not definitely state how long the antibodies stay in the baby.

However, she noted, “the presence of these antibodies in the cord blood, which is the foetus’ blood, indicates that the baby also has potential to derive benefits from maternal vaccination”.